SAREPTA THERAPEUTICS ANNOUNCES THAT PHASE 1/2a DUCHENNE MUSCULAR DYSTROPHY (DMD) MICRO- DYSTROPHIN GENE THERAPY TRIAL PLACED ON CLINICAL HOLD DUE TO AN OUT-OF-SPECIFICATION PRODUCTION LOT; NO OBSERVED SAFETY EVENTS da Admin | Lug 25, 2018 | Clinical“http://investorrelations.sarepta.com”
SAREPTA THERAPEUTICS ANNOUNCES THAT PHASE 1/2a DUCHENNE MUSCULAR DYSTROPHY (DMD) MICRO- DYSTROPHIN GENE THERAPY TRIAL PLACED ON CLINICAL HOLD DUE TO AN OUT-OF-SPECIFICATION PRODUCTION LOT; NO OBSERVED SAFETY EVENTS da Admin | Lug 25, 2018 | Clinica“http://investorrelations.sarepta.com”
PROCEDURAL ADVICE ON THE EVALUATION OF ADVANCED THERAPY MEDICINAL PRODUCT IN ACCORDANCE WITH ARTICLE 8 OF REGULATION (EC) NO 1394/2007 da Admin | Gen 25, 2018 | Regulatory“http://www.ema.europa.eu”
PROCEDURAL ADVICE ON THE EVALUATION OF ADVANCED THERAPY MEDICINAL PRODUCT IN ACCORDANCE WITH ARTICLE 8 OF REGULATION (EC) NO 1394/2007 da Admin | Gen 25, 2018 | Regolatorio“http://www.ema.europa.eu”
GUIDELINE ON SAFETY AND EFFICACY FOLLOW-UP AND RISK 6 MANAGEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS da Admin | Gen 25, 2018 | Regulatory“http://www.ema.europa.eu”